These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 28445152)

  • 101. Differences in immunohistochemical biomarkers between intra- and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
    Wiggers JK; Ruys AT; Groot Koerkamp B; Beuers U; ten Kate FJ; van Gulik TM
    J Gastroenterol Hepatol; 2014 Aug; 29(8):1582-94. PubMed ID: 24787096
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Expression of FGF8, FGF18, and FGFR4 in Gastroesophageal Adenocarcinomas.
    Jomrich G; Hudec X; Harpain F; Winkler D; Timelthaler G; Mohr T; Marian B; Schoppmann SF
    Cells; 2019 Sep; 8(9):. PubMed ID: 31527546
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Different iron-handling in inflamed small and large cholangiocytes and in small and large-duct type intrahepatic cholangiocarcinoma.
    Mancinelli R; Cutone A; Rosa L; Lepanto MS; Onori P; Pannarale L; Franchitto A; Gaudio E; Valenti P
    Eur J Histochem; 2020 Oct; 64(4):. PubMed ID: 33131269
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Analysis of N-linked Glycan Alterations in Tissue and Serum Reveals Promising Biomarkers for Intrahepatic Cholangiocarcinoma.
    Ochoa-Rios S; Blaschke CRK; Wang M; Peterson KD; DelaCourt A; Grauzam SE; Lewin D; Angel P; Roberts LR; Drake R; Mehta AS
    Cancer Res Commun; 2023 Mar; 3(3):383-394. PubMed ID: 36890858
    [TBL] [Abstract][Full Text] [Related]  

  • 105. SSH1 promotes progression of intrahepatic cholangiocarcinoma via p38 MAPK-CXCL8 axis.
    Chen F; Aye L; Yu L; Liu L; Liu Y; Lin Y; Gao D; Gao Q; Zhang S
    Carcinogenesis; 2023 May; 44(3):232-241. PubMed ID: 36857607
    [TBL] [Abstract][Full Text] [Related]  

  • 106. FGFR4 provides the conduit to facilitate FGF19 signaling in breast cancer progression.
    Zhao X; Xu F; Dominguez NP; Xiong Y; Xiong Z; Peng H; Shay C; Teng Y
    Mol Carcinog; 2018 Nov; 57(11):1616-1625. PubMed ID: 30074276
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker.
    Byrling J; Kristl T; Hu D; Pla I; Sanchez A; Sasor A; Andersson R; Marko-Varga G; Andersson B
    J Transl Med; 2020 Sep; 18(1):343. PubMed ID: 32887625
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Carbohydrate Antigen 50: Values for Diagnosis and Prognostic Prediction of Intrahepatic Cholangiocarcinoma.
    Luang S; Teeravirote K; Saentaweesuk W; Ma-In P; Silsirivanit A
    Medicina (Kaunas); 2020 Nov; 56(11):. PubMed ID: 33207685
    [No Abstract]   [Full Text] [Related]  

  • 109. Clinicopathological significance of olfactomedin-4 in extrahepatic bile duct carcinoma.
    Jun SY; An S; Huh T; Chung JY; Hong SM
    Pathol Res Pract; 2020 May; 216(5):152940. PubMed ID: 32276789
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma: Real-life Data on Liver Disease, Treatment and Prognosis.
    Adhoute X; Pietri O; Pénaranda G; Wolf T; Beaurain P; Monnet O; Laquière A; Bonomini J; Neumann F; Levrel O; Buono JP; Hanna X; Castellani P; Perrier H; Bourliere M; Anty R
    J Clin Transl Hepatol; 2023 Oct; 11(5):1106-1117. PubMed ID: 37577232
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Intratumoral heterogeneity of intrahepatic cholangiocarcinoma.
    Walter D; Döring C; Feldhahn M; Battke F; Hartmann S; Winkelmann R; Schneider M; Bankov K; Schnitzbauer A; Zeuzem S; Hansmann ML; Peveling-Oberhag J
    Oncotarget; 2017 Feb; 8(9):14957-14968. PubMed ID: 28146430
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Mutations of candidate tumor suppressor genes at chromosome 3p in intrahepatic cholangiocarcinoma.
    You HL; Huang WT; Liu TT; Weng SW; Eng HL
    Exp Mol Pathol; 2017 Dec; 103(3):249-254. PubMed ID: 29122566
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Update on the association of hepatitis B with intrahepatic cholangiocarcinoma: Is there new evidence?
    Fragkou N; Sideras L; Panas P; Emmanouilides C; Sinakos E
    World J Gastroenterol; 2021 Jul; 27(27):4252-4275. PubMed ID: 34366604
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Distribution and density of tertiary lymphoid structures predict clinical outcome in intrahepatic cholangiocarcinoma.
    Ding GY; Ma JQ; Yun JP; Chen X; Ling Y; Zhang S; Shi JY; Chang YQ; Ji Y; Wang XY; Tan WM; Yuan KF; Yan B; Zhang XM; Liang F; Zhou J; Fan J; Zeng Y; Cai MY; Gao Q
    J Hepatol; 2022 Mar; 76(3):608-618. PubMed ID: 34793865
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Novel cell subtypes of SPP1 + S100P+, MS4A1-SPP1 + S100P+ were key subpopulations in intrahepatic cholangiocarcinoma.
    Xuan Z; Liu L; Zhang G; Zheng X; Jiang J; Wang K; Huang P
    Biochim Biophys Acta Gen Subj; 2023 Sep; 1867(9):130420. PubMed ID: 37433400
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.
    Sirica AE; Strazzabosco M; Cadamuro M
    Adv Cancer Res; 2021; 149():321-387. PubMed ID: 33579427
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Survival and Causes of Death among Patients with Intrahepatic Cholangiocarcinoma in the United States from 2000 to 2018.
    Elgenidy A; Afifi AM; Jalal PK
    Cancer Epidemiol Biomarkers Prev; 2022 Dec; 31(12):2169-2176. PubMed ID: 36099432
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Investigation of the Proliferative Potential of FGF21 or FGF19 in Liver-Specific FGFR4-Deficient Mice.
    Wäse K; Bartels T; Schwahn U; Kabiri M
    Toxicol Pathol; 2023 Jan; 51(1-2):27-38. PubMed ID: 37098695
    [TBL] [Abstract][Full Text] [Related]  

  • 119. FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.
    Weiss A; Adler F; Buhles A; Stamm C; Fairhurst RA; Kiffe M; Sterker D; Centeleghe M; Wartmann M; Kinyamu-Akunda J; Schadt HS; Couttet P; Wolf A; Wang Y; Barzaghi-Rinaudo P; Murakami M; Kauffmann A; Knoepfel T; Buschmann N; Leblanc C; Mah R; Furet P; Blank J; Hofmann F; Sellers WR; Graus Porta D
    Mol Cancer Ther; 2019 Dec; 18(12):2194-2206. PubMed ID: 31409633
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Improving patient selection for selective internal radiation therapy of intra-hepatic cholangiocarcinoma: A meta-regression study.
    Cucchetti A; Cappelli A; Mosconi C; Zhong JH; Cescon M; Pinna AD; Golfieri R
    Liver Int; 2017 Jul; 37(7):1056-1064. PubMed ID: 28177190
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.